injection site reaction from tirzepatide Tirzepatide: Causes, Management and Prevention Tirzepatide Injection Site Red and

They were disappointed by a non-significant 0.5% reduction in A1c among patients taking the drug, compared to a 0.3% reduction in the placebo group, all of whom had poorly controlled A1c levels above 8%

Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis

When used under professional supervision, GLP-1 therapies can lead to clinically meaningful and sustainable weight loss , while also helping to manage metabolic health and reduce the risk of obesity-related conditions

PlexusDx clinicians counsel all female patients of reproductive age about these dynamics before initiating tirzepatide

N Engl J Med 392(6):612615 Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA